The EU Commission proposes updates to EU pharmaceutical legislation
The EU Commission proposes reform to the current EU pharmceutical legislation in regard to the protection of data and the use of generics and biosimilars for drug companies in the EU.
Members of the European Parliament (MEPs) took their stance on a reform of EU pharmaceutical legislation, opening the floor for negotiations with member states to begin, ahead of final decisions being made after the European elections in June 2024.
“Today’s vote is a step towards delivering the tools to tackle present and future healthcare challenges, particularly for our market attractiveness and access to medicine across EU countries,” said Pernille Weiss, rapporteur for the file alongside Tiemo Wölken.
The proposed legislation has sparked some controversy as it marks the most significant reform in pharmaceutical legislation in more than 20 years, leading to much back and forth over whether to prioritise patient access compared to innovation in medicine development.
The Commission was advocating for reducing the baseline regulatory data protection from 8 years to 6 years. The current data protection window means that companies cannot access or use clinical trial data from other companies that has been submitted to the European Medicines Agency for marketing approval in this time, with two additional years of market protection for the product where generics or biosimilars cannot be marketed.
The initial proposal also included scope for extensions to the data protection, for example for another 2 years of protection if a company launches a drug in all EU member states. However, industry leaders advised against this citing that companies can exert no control over the timing of pricing and reimbursement decisions in each country, which regularly leads to delays.
As a compromise, the MEPs instead suggested that the countries themselves should be responsible for requesting pricing and reimbursement applications from the prospective companies. Then, they were further able to negotiate a time period of 7.5 years for regulatory protection for access to clinical trial data, and the additional 2 years for market protection.
There are some exceptions to the rule of course, where some medicines are specifically designed to address an area of unmet need, along wither certain other criteria including conducting comparative clinical trials, a large proportion of the R&D taking lace in the EU and in association with EU research entities. The extension here could be granted up to 8.5 years of protection.
Another exception where a 12-month extension can be gained is if the drug gains authorisation for another therapeutic indication, with significant benefits when compared to already market-available therapies.
When it comes to treating rare diseases, orphan drugs, which meet the requirements of an area of high unmet medical need, can receive up to 11 years of data protection.
Source:
Science Business. European Parliament approves pharma reform compromise. [Date accessed 12/04/2024] https://sciencebusiness.net/news/data/european-parliament-approves-pharma-reform-compromise
Related News
-
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News Special Edition Women in Pharma: Women’s health and the pharmaceutical industry
International Women’s Day is an annual celebration of women around the world every March 8. March also marks Women’s History Month. This March, our Women in Pharma series takes a look at how women’s healthcare has developed, and the r... -
News Informa Markets International Women’s Day Panel Discussion
On March 7, 2024, the Informa Markets Amsterdam office hosted an International Women’s Day Breakfast and Panel Discussion to celebrate the women who drive the B2B events industry forward, including members of the CPHI team. -
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News CPHI Podcast Series: What to expect from novel excipients?
In this month's episode of the CPHI Podcast Series, Digital Editor Lucy Chard is joined by Nick DiFranco, the Global Market Manager for Novel Pharmaceutical Excipients at Lubrizol Life Science to discuss the ins and outs of excipients, how the... -
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to... -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance